Clinical Nuclear Medicine
Radioiodine in Low-risk Differentiated Thyroid Cancer
The management of differentiated thyroid cancer (DTC) has undergone a major paradigm shift over the past decade, with increasing emphasis on treatment de-escalation and avoidance of overtreatment in patients with low-risk disease. The 2015 American Thyroid Association guidelines marked a turning point by discouraging routine postoperative radioiodine (RAI) remnant ablation in low-risk patients, reflecting the excellent prognosis of most papillary thyroid carcinomas and concerns regarding unnecessary therapy-related …